Miroslav Vlcek

Miroslav Vlcek

Auto-generated profile, based on publicly available information

Miroslav Vlcek

Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in Autonomic Neuroscience
Verified
Journal Article
Closed access
MVMiroslav Vlcek
Miroslav Vlcek
ZRZofia Radikova
Zofia Radikova
APAdela Penesova
Adela Penesova
RKRichard Kvetnansky
Richard Kvetnansky
RIRichard Imrich
Richard Imrich

1 July 2020 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
HKHana H. Kutlikova
Hana H. Kutlikova
JDJaroslava Babková Durdiaková
Jaroslava Babková Durdiaková
BWBernhard Wagner
Bernhard Wagner
MVMiroslav Vlček
Miroslav Vlček
CEChristoph Eisenegger
Christoph Eisenegger
IRIgor Riečanský
Igor Riečanský

1 January 2014 in General Physiology and Biophysics
Verified
Journal Article
Closed access
LCLucia Chovanova
Lucia Chovanova
MVMiroslav Vlcek
Miroslav Vlcek
KKKatarina Krskova
Katarina Krskova
APAdela Penesova
Adela Penesova
ŽRŽofia Rádiková
Žofia Rádiková
RIRichard Imrich
Richard Imrich
Increased production of IL-6 and IL-17 in lipopolysaccharide-stimulated peripheral mononuclears from patients with rheumatoid arthritis

5 February 2012 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
MVMiroslav Vlcek
Miroslav Vlcek
JRJozef Rovensky
Jozef Rovensky
GEGraeme Eisenhofer
Graeme Eisenhofer
ZRZofia Radikova
Zofia Radikova
APAdela Penesova
Adela Penesova
RIRichard Imrich
Richard Imrich

11 December 2008 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MVMiroslav Vlcek
Miroslav Vlcek
JRJozef Rovensky
Jozef Rovensky
PBPavel Blazicek
Pavel Blazicek
ZRZofia Radikova
Zofia Radikova
APAdela Penesova
Adela Penesova
RIRichard Imrich
Richard Imrich

Verified
Journal Article
Open access
PDF file
MHMiroslava Hardonova
Miroslava Hardonova
PSPavel Siarnik
Pavel Siarnik
MSMonika Sivakova
Monika Sivakova
BSBianka Sucha
Bianka Sucha
APAdela Penesova
Adela Penesova
PTPeter Turcani
Peter Turcani
Introduction: Epidemiological studies have suggested an increased vascular risk in patients with multiple sclerosis (MS). There is increasing evidence of the beneficial effects of GLP-1 agonists (GLP-1a) in preventing vascular complications and slowing the progression of neurodegeneration. Our objective was to explore the changes in the endothelial function of MS patients after 12 months of GLP-1a therapy. We also explored the role of lipoprotein subfractions and the antioxidant capacity of plasma. Methods: MS patients were enrolled in a prospective, unicentric study. GLP-1a (dulaglutide) was administered to 13 patients. The control population consisted of 12 subjects. Endothelial function was determined by peripheral arterial tonometry and expressed as reperfusion hyperemia index (RHI). Trolox equivalent antioxidant capacity (TEAC) was used to assess the total antioxidant capacity of the plasma. The levels of lipoprotein subfractions were evaluated. Results: The GLP-1a group did not have a significant change in their RHIs after 12 months (2.1 ± 0.6 vs. 2.1 ± 0.7; p = 0.807). However, a significant increase in their TEACs was observed (4.1 ± 1.4 vs. 5.2 ± 0.5 mmol/L, p = 0.010). On the contrary, the subjects in the control group had a significant worsening of their RHIs (2.1 ± 0.5 vs. 1.8 ± 0.6; p = 0.030), without significant changes in their TEACs. Except for a significant decrease in very-low-density lipoprotein (VLDL) (30.8 ± 10.2 vs. 22.6 ± 8.3 mg/dL, p = 0.043), no other significant changes in the variables were observed in the control group. VLDL levels (beta = −0.637, p = 0.001), the use of GLP-1a therapy (beta = 0.560, p = 0.003), and small LDL (beta = 0.339, p = 0.043) were the only significant variables in the model that predicted the follow-up RHI. Conclusion: Our results suggest that the application of additional GLP-1a therapy may have atheroprotective and antioxidant effects in MS patients with high MS activity and thus may prospectively mitigate their vascular risk. However, the lipoprotein profile may also play an important role in the atherogenic risk of MS subjects.